These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2113148)

  • 1. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
    Muraki J
    Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sequential combination therapy with alpha interferon and OK-432 (streptococcal preparation) against advanced renal cell carcinoma].
    Marumo K; Mura M; Deguchi N; Baba S; Jitsukawa S; Nakazono M; Tazaki H
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2434-9. PubMed ID: 3729498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes.
    Mizutani Y; Nio Y; Yoshida O
    Cancer; 1992 Jun; 69(12):2999-3007. PubMed ID: 1591693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of selective intra-arterial infusion of OK-432 against renal cell cancers].
    Fujioka T; Tanji S; Koike H; Kumagai K; Suzuki K; Aoki H; Banya Y; Kubo T; Ohhori T
    Hinyokika Kiyo; 1987 Jun; 33(6):832-7. PubMed ID: 3673835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of advanced renal cell carcinoma achieved complete response by a sequential combination therapy with gamma interferon and OK-432 (streptococcal preparation)].
    Nakamura S; Marumo K; Shibayama T; Baba S; Deguchi N; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1103-7. PubMed ID: 3141666
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-alpha in patients with renal cell carcinoma].
    Kubota S
    Nihon Hinyokika Gakkai Zasshi; 1992 Nov; 83(11):1781-8. PubMed ID: 1479751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients.
    Sobota V; Bubeník J; Indrová M; Vlk V; Jakoubková J
    J Immunol Methods; 1997 Apr; 203(1):1-10. PubMed ID: 9134025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer.
    Sato M; Yoshida H; Yanagawa T; Yura Y; Urata M; Atsumi M; Hayashi Y; Takegawa Y
    Int J Oral Surg; 1984 Feb; 13(1):7-15. PubMed ID: 6203858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
    Ujiie T
    Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction by OK-432 of the monolayer contact-mediated inhibition of human natural killer cell activity.
    Yagita M; Saksela E
    Immunol Lett; 1990 Sep; 25(4):347-53. PubMed ID: 2249878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of soluble factors derived from oral cancer cells on the production of interferon-γ from peripheral blood mononuclear cells following stimulation with OK-432.
    Ohe G; Sasai A; Uchida D; Tamatani T; Nagai H; Miyamoto Y
    Oncol Rep; 2013 Aug; 30(2):945-51. PubMed ID: 23685791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells.
    Bonavida B; Katz J; Hoshino T
    Cell Immunol; 1986 Oct; 102(1):126-35. PubMed ID: 3492275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
    Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
    J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enhancing effects on interferon-gamma production by combination of OK-432 and interferon-alpha in patients with head and neck cancer].
    Sugiyama M; Morisaki N; Konishi K; Go K; Sugita M; Nakai Y
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2200-6. PubMed ID: 6435540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of human peripheral blood-derived monocytes by OK-432 (Streptococcus pyogenes): augmented cytotoxicity and secretion of TNF and synergy with rIFN-gamma.
    Bonavida B; Jewett A
    Cell Immunol; 1989 Oct; 123(2):373-83. PubMed ID: 2507170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of the activating effects of recombinant human interleukin 2 and interferon-gamma on cell-mediated cytotoxicity against renal cell carcinoma in vitro].
    Marumo K; Ueno M; Baba S; Muraki J; Deguchi N; Tazaki H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1825-9. PubMed ID: 3109327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: combination effect of OK-432 and recombinant lymphokines.
    Nanjo M; Moriya Y; Hashimoto S; Kataoka M; Saito M; Yoshida T; Ishida N
    Int J Immunopharmacol; 1991; 13(2-3):205-15. PubMed ID: 1906439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.